{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T08:47:38Z","timestamp":1758444458296,"version":"3.44.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1002\/jps.24432","type":"journal-article","created":{"date-parts":[[2015,3,27]],"date-time":"2015-03-27T18:08:42Z","timestamp":1427479722000},"page":"3194-3198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prediction of Pharmacokinetics and Pharmacodynamics of Doripenem in Pediatric Patients"],"prefix":"10.1016","volume":"104","author":[{"given":"Yumiko","family":"Matsuo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Shimamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Wajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1002\/jps.24432_bb0005","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/510079","article-title":"Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It\u2019s not just for mice anymore","volume":"44","author":"Ambrose","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1002\/jps.24432_bb0010","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1086\/344653","article-title":"Prevention of resistance: A goal for dose selection for antimicrobial agents","volume":"36","author":"Durusano","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1002\/jps.24432_bb0015","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s10156-003-0279-X","article-title":"Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling","volume":"9","author":"Nicolau","year":"2003","journal-title":"J Infect Chemother"},{"key":"10.1002\/jps.24432_bb0020","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/00148581-200608020-00005","article-title":"Pharmacodynamic evaluation of meropenem and cefotaxime for pediatric meningitis: A report from the OPTAMA program","volume":"8","author":"Ellis","year":"2006","journal-title":"Pediatr Drugs"},{"key":"10.1002\/jps.24432_bb0025","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1128\/AAC.48.7.2464-2470.2004","article-title":"Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: Data collected in North America in 2002","volume":"48","author":"Kuti","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.24432_bb0030","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1177\/0091270003257225","article-title":"Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem","volume":"43","author":"Kuti","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1002\/jps.24432_bb0035","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1128\/AAC.01128-07","article-title":"In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacteria isolates from infected diabetic foot wounds","volume":"52","author":"Goldstein","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.24432_bb0040","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","article-title":"Comparative review of the carbapenems","volume":"67","author":"Zhanel","year":"2007","journal-title":"Drugs"},{"issue":"S-1","key":"10.1002\/jps.24432_bb0045","first-page":"1","article-title":"In vitro and in vivo antibacterial activity of doripenem, a new carbepenem. Jpn\u201d","volume":"53","author":"Tsuji","year":"2005","journal-title":"J Chemother"},{"issue":"S-1","key":"10.1002\/jps.24432_bb0050","first-page":"17","article-title":"In vitro activity of doripenem against gram-positive and gram-negative bacteria isolates. Jpn\u201d","volume":"53","author":"Kuwahara-Arai","year":"2005","journal-title":"J Chemother"},{"issue":"S-1","key":"10.1002\/jps.24432_bb0055","first-page":"80","article-title":"Antipseudomonal activity of doripenem, a novel parenteral carbapenem antibiotic. Jpn\u201d","volume":"53","author":"Miwa","year":"2005","journal-title":"J Chemother"},{"key":"10.1002\/jps.24432_bb0060","unstructured":"Finibax Japanese package insert. Accessed on, at: http:\/\/www.info.pmda.go.jp\/go\/pack\/6139402D1032_1_04\/."},{"article-title":"Pharmacokinetics of doripenem at 1g and 2g in healthy volunteers and patients with serious infection","year":"2010","author":"Wajima","key":"10.1002\/jps.24432_bb0065"},{"key":"10.1002\/jps.24432_bb0070","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF01062336","article-title":"Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics","volume":"10","author":"Boxenbaum","year":"1982","journal-title":"J Pharm Biopharm"},{"year":"2005","series-title":"Interspecies pharmacokinetic scaling: Principles and application of allometric scaling","author":"Mahmood","key":"10.1002\/jps.24432_bb0075"},{"key":"10.1002\/jps.24432_bb0080","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-199630050-00001","article-title":"A size standard for pharmacokinetics","volume":"30","author":"Holford","year":"1996","journal-title":"Clin Pharm"},{"key":"10.1002\/jps.24432_bb0085","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/00003088-199733050-00001","article-title":"Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients","volume":"33","author":"Anderson","year":"1997","journal-title":"Clin Pharm"},{"key":"10.1002\/jps.24432_bb0090","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1002\/jps.20977","article-title":"Pharmacokinetic prediction for intravenous \u03b2-lactam antibiotics in pediatric patients","volume":"96","author":"Shimamura","year":"2007","journal-title":"J Pharm Sci"},{"year":"1992","series-title":"NONMEM users guide","author":"Boeckmann","key":"10.1002\/jps.24432_bb0095"},{"issue":"S-1","key":"10.1002\/jps.24432_bb0100","first-page":"104","article-title":"Phase 1 study of doripenem, a new carbapenem antibiotic for injection in healthy volunteers. Jpn\u201d","volume":"53","author":"Nakashima","year":"2005","journal-title":"J Chemother"},{"key":"10.1002\/jps.24432_bb0105","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/jps.20099","article-title":"Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles","volume":"93","author":"Wajima","year":"2004","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.24432_bb0110","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1128\/AAC.01649-09","article-title":"Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients","volume":"54","author":"Nandy","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.24432_bb0115","first-page":"762","article-title":"Clinical study of meropenem for infections in the pediatric field","volume":"51","author":"Toyonaga","year":"2003","journal-title":"Jpn J Chemother"},{"key":"10.1002\/jps.24432_bb0120","first-page":"543","article-title":"Antimicrobial susceptibility of clinical isolates of aerobic Gram-positive cocci and anaerobic bacteria in 2004","volume":"56","author":"Fujimura","year":"2008","journal-title":"Jpn J Chemother"},{"key":"10.1002\/jps.24432_bb0125","first-page":"562","article-title":"Antimicrobial susceptibility of clinical isolates of aerobic Gram-negative bacteria in 2004","volume":"56","author":"Yoshida","year":"2008","journal-title":"Jpn J Chemother"},{"article-title":"Pharmacokinetics\/pharmacodynamics of doripenem (DRPM) in Japanese pediatric patients","year":"2011","author":"Totsuka","key":"10.1002\/jps.24432_bb0130"},{"key":"10.1002\/jps.24432_bb0135","unstructured":"Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Food and Drug Administration. Guidance for industry: Exposure-response relationships\u2014Study design, data analysis, and regulatory applications. Accessed on, at: http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm072109.pdf"},{"article-title":"Efficacy and safety of doripenem (DRPM) in pediatric patients","year":"2011","author":"Sunakawa","key":"10.1002\/jps.24432_bb0140"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916300995?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916300995?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:27:07Z","timestamp":1758360427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354916300995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0022354916300995"],"URL":"https:\/\/doi.org\/10.1002\/jps.24432","relation":{},"ISSN":["0022-3549"],"issn-type":[{"type":"print","value":"0022-3549"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediction of Pharmacokinetics and Pharmacodynamics of Doripenem in Pediatric Patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/jps.24432","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Wiley Periodicals, Inc. and the American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}